Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: advanced NSCLC received the TROP2-directed ADC datopotamab deruxtecan (Dato-DXd)
I · Intervention 중재 / 시술
the TROP2-directed ADC datopotamab deruxtecan (Dato-DXd)
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Conversely, the activation of immune-related pathways was associated with treatment response. Validation of these findings in phase III studies will be essential to define biomarkers, ultimately enabling more precise identification of patients most likely to benefit from Dato-DXd.
OpenAlex 토픽 ·
Lung Cancer Treatments and Mutations
Lung Cancer Research Studies
Lung Cancer Diagnosis and Treatment
Antibody-drug conjugates (ADCs) are rapidly transforming the treatment landscape of advanced non-small cell lung cancer (NSCLC), yet validated predictive biomarkers to guide their use remain lacking.
APA
David Planchard, Nathalie Cozic, et al. (2026). Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study.. Cancer cell. https://doi.org/10.1016/j.ccell.2026.03.017
MLA
David Planchard, et al.. "Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study.." Cancer cell, 2026.
PMID
41999747 ↗
Abstract 한글 요약
Antibody-drug conjugates (ADCs) are rapidly transforming the treatment landscape of advanced non-small cell lung cancer (NSCLC), yet validated predictive biomarkers to guide their use remain lacking. ICARUS-LUNG01 is a prospective, phase II study designed to integrate clinical outcomes with longitudinal translational analyses. In this multicenter trial, 100 pretreated patients with advanced NSCLC received the TROP2-directed ADC datopotamab deruxtecan (Dato-DXd). The study reported an objective response rate (ORR) of 26.0%, with a median progression-free survival (PFS) of 3.6 months, and a greater benefit observed in non-squamous tumors. Baseline and on-treatment tumor analyses suggested that resistance to Dato-DXd could be associated with a lack of TROP2 cytoplasmic staining and the early activation of DNA repair pathways. Conversely, the activation of immune-related pathways was associated with treatment response. Validation of these findings in phase III studies will be essential to define biomarkers, ultimately enabling more precise identification of patients most likely to benefit from Dato-DXd.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (2)
- Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAF-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison.
- Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Role of Cytokines in Oligometastatic Non-Small-Cell Lung Cancer Treated with Stereotactic Radiation Therapy: An Observational Pilot Study.
- Development and validation of a novel nomogram model for predicting postoperative survival of T4N0M0 NSCLC: a population-based survival analysis.
- Cost comparison of osimertinib plus platinum-pemetrexed versus amivantamab plus lazertinib for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
- RBM15 Mediated m6A Modification of SRSF1 Inhibits Cuproptosis in Non-Small Cell Lung Cancer by Mediating ATP7B Alternative Splicing.
- DIP-like Adenocarcinoma Presenting as a Part-Solid Nodule: A Case Report.
- Targeting Mesenchymal-Epidermal Transition (MET) Aberrations in Non-Small Cell Lung Cancer: Current Challenges and Therapeutic Advances.